Private Advisor Group, LLC Fate Therapeutics Inc Transaction History

Private Advisor Group, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 13, 2022	SELL	$17.78 - $42.39 $168,572 - $401,899	-9,481 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$29.67 - $60.28 $57,500 - $116,822	1,938 Added 25.69%	9,481 $367,000
Q4 2021 Feb 10, 2022	SELL	$47.84 - $64.34 $227,574 - $306,065	-4,757 Reduced 38.67%	7,543 $442,000
Q3 2021 Oct 14, 2021	BUY	$59.27 - $95.73 $358,227 - $578,592	6,044 Added 96.61%	12,300 $730,000
Q2 2021 Aug 12, 2021	BUY	$67.25 - $92.52 $2,555 - $3,515	38 Added 0.61%	6,256 $543,000
Q1 2021 Apr 22, 2021	BUY	$72.16 - $117.4 $6,855 - $11,153	95 Added 1.55%	6,218 $512,000
Q4 2020 Apr 01, 2021	BUY	$38.09 - $100.95 $42,775 - $113,366	1,123 Added 22.46%	6,123 $557,000
Q2 2020 Aug 17, 2020	BUY	$20.21 - $35.23 $101,050 - $176,149	5,000 New	5,000 $172,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $215M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Private Advisor Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Private Advisor Group, LLC with notifications on news.